Anti-Human IgE (Omalizumab) (I-2190-1.0mg)

IgE is a pivotal antibody in allergic responses, crucially involved in conditions like allergic asthma. It binds to high-affinity receptors on mast cells and basophils, triggering the release of inflammatory mediators. The pathogenic role of IgE in allergic inflammation is well- documented, with multivalent allergens binding to allergen-specific IgEs on sensitized effector cells, leading to effector cell activation and the release of potent inflammatory mediators. Therapies targeting IgE, such as omalizumab, have shown efficacy in reducing exacerbations, symptoms, and medication use in allergic asthma, highlighting the significance of IgE in allergic diseases1,2. RG-3648, commonly known as Omalizumab, is a humanized monoclonal antibody that targets IgE, a key player in allergic responses. Approved for severe allergic asthma and chronic spontaneous urticaria, Omalizumab binds to serum IgE, preventing its interaction with cellular IgE receptors. By downregulating high-affinity IgE receptors on inflammatory cells and reducing eosinophil numbers, Omalizumab improves respiratory symptoms, and quality of life, and reduces asthma exacerbations. Despite generally being well-tolerated, rare anaphylactic reactions have been reported. Omalizumab's efficacy extends to various conditions like allergic rhinitis, atopic dermatitis, and nasal polyps, showcasing its therapeutic versatility3,4.